

VALBIOTIS TO PRESENT THE RESULTS OF ITS PHASE I/II CLINICAL STUDY ON TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA[®], AT THE AMERICAN DIABETES ASSOCIATION'S 77TH SCIENTIFIC SESSION

La Rochelle (France), March 30th, 2017 - VALBIOTIS, a company that specializes in developing innovative nutrition solutions designed to prevent cardio-metabolic disease and provide nutritional support for patients, has announced today that it will present an overview of the results of its Phase I/II clinical study on Totum-63, the active ingredient of Valedia[®], at the 77th scientific session of the American Diabetes Association (ADA). The event will take place from 9 to 13 June 2017 in San Diego (California, USA).

The ADA scientific sessions are held every year and are recognized as the world's most prominent meetings on diabetes. Each year, over 13,000 people attend: researchers, health professionals and manufacturers. These sessions offer participants the opportunity to present pioneering research and the latest advances in diabetes treatment and care.¹

Valedia[®], which contains the active ingredient Totum-63, is an innovative and patented combination of plant extracts designed to prevent type 2 diabetes.

Diabetes now affects over 415 million people worldwide. The disease causes serious complications which led to over 5 million deaths in 2015 and cost approximately 673 billion dollars in global health expenditure.

Although type 2 diabetes (once diagnosed) is irreversible in the vast majority of cases, its risk condition, pre-diabetes, which is defined by the American Diabetes Association as a fasting plasma glucose level between 100 mg/dL and 125 mg/dL, is reversible.

Managing pre-diabetes would make it possible to defer the disease or even to revert to a healthy physiological state.

VALEDIA[®] IS A WORLD PREMIERE FOR 527 MILLION PRE-DIABETICS AND THE AIM IS TO MARKET IT FROM THE YEAR 2020

The Phase I/II clinical study, for which all results will be presented to the ADA, was particularly aimed at validating the safety of the product for human use.

"The American Diabetes Association's scientific sessions are prestigious international events in our sector. VALBIOTIS has been selected for the second consecutive year, which highlights the relevance of our work and is proof of the increasing interest that it is generating. On this esteemed occasion, we are thrilled to be able to present the results of the Phase I/II clinical study on the active ingredient of Valedia[®] to the biggest professional and academic stakeholders in the field, and to once again demonstrate VALBIOTIS' ambition to achieve a zero-diabetes world," commented Sébastien Peltier, the company's CEO.

¹ For more information, visit: <http://professional.diabetes.org/meeting/scientific-sessions/77th-scientific-sessions>



ABOUT VALBIOTIS

VALBIOTIS is a company that specializes in developing innovative nutrition solutions designed to prevent cardio-metabolic disease and to provide nutritional support for patients. Valbiotis products are made for stakeholders in the food, medical nutrition, and pharmaceutical industries. VALBIOTIS has a particular focus on preventing type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular disease.

Valbiotis was founded in La Rochelle in 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. Valbiotis is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

For more information, visit

www.valbiotis.com

CONTACTS

VALBIOTIS
Sébastien Peltier, CEO

PRESS RELATIONS
ALIZE RP
Caroline Carmagnol / Wendy Rigal
+33 1 44 54 36 66
valbiotis@alizerp.com